Infirmacea Inc.

Infirmacea is a preclinical-stage biotechnology company developing a DNA medicine platform designed to enable the body to produce therapeutic proteins internally. The company utilizes naked DNA as its therapeutic modality, which is selected for its safety and ease of manufacturing. To address the historical challenge of inefficient gene expression in vivo, Infirmacea developed a proprietary gene expression enhancer called gBoost™. This technology enhances gene expression across various genetic modalities, including plasmid DNA, mRNA, and viral vectors like AAV, by improving intracellular processing and transcriptional efficiency. The platform is designed for delivery to skeletal muscle using needle-free jet injection, allowing for sustained protein production with minimal DNA doses.

By prioritizing minimal genetic material, durable protein expression, and patient-friendly delivery, the company aims to reduce the treatment burden associated with traditional protein-based medicines that require frequent injections. Infirmacea’s approach focuses on areas where long-term safety and treatment durability are critical, such as pediatric, chronic, and age-related musculoskeletal conditions. The company is actively exploring the potential of its platform across diverse disease areas, including growth hormone deficiency, hypoparathyroidism, and conditions related to musculoskeletal aging, while seeking strategic collaborations to advance these exploratory therapeutic applications.